Vitamin D supplementation for cystic fibrosis.

What It Covers

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a systematic review.

To assess the effects of vitamin D supplementation on the frequency of vitamin D deficiency, respiratory outcomes and vitamin D toxicity in the CF population.

Why It Was Studied

Cystic fibrosis (CF) is a genetic disorder with multiorgan effects.

In a subgroup with pancreatic insufficiency malabsorption of the fat soluble vitamins (A, D, E, K) may occur.

Who the Included Studies Covered

By PubMed's age tags, the people studied were children and adults.

How the Review Was Done

The researchers searched the Cochrane CF and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent search: 15 February 2012.

What Was Measured

Both authors independently assessed the 'risk of bias' of each included trial and extracted outcome data (from published trial information) for assessment of bone mineralization, growth and nutritional status, frequency of vitamin D deficiency, respiratory status, quality of life and adverse events.

PubMed files the paper under topics including Bone Density Conservation Agents, Bone Diseases, Metabolic, Calcitriol, Calcium, Dietary, Cystic Fibrosis, Dietary Supplements and Exocrine Pancreatic Insufficiency.

What This Means in Plain Language

This is a systematic review of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (The Cochrane database of systematic reviews), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.